Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
diabetic renal dysfunction
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "diabetic renal dysfunction" in MCE Product Catalog:
14
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
Enalapril (MK-421) is an orally active angiotensin-converting enzyme inhibitor. Enalapril blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .
14
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
Enalapril maleate (MK-421 maleate) is an orally active angiotensin-converting enzyme inhibitor. Enalapril maleate blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril maleate inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril maleate attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril maleate reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril maleate is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .
Category:
Human Gut Microbiota Metabolites Natural Products Metabolic Disease Endogenous metabolite Disease Research Fields
Target:
Cat. No.: HY-B0331AR
CAS No.: 76095-16-4
Synonyms: MK-421 maleate (Standard)
Target:
Reference Standards Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS)
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
Enalapril maleate (Standard) (MK-421 maleate (Standard)) is the analytical standard of Enalapril maleate (HY-B0331A). This product is intended for research and analytical applications. Enalapril maleate is an orally active angiotensin-converting enzyme inhibitor. Enalapril maleate blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril maleate inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril maleate attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril maleate reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril maleate is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .
Cat. No.: HY-N10423
CAS No.: 18423-69-3
Synonyms: (-)-Cubebin
Cat. No.: HY-B0331AS
CAS No.: 349554-02-5
Synonyms: MK-421-d5maleate
Target:
Isotope-Labeled Compounds Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS)
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
Enalapril-d5 maleate (MK-421 D5 maleate) is the deuterated-labeled Enalapril maleate (HY-B0331A). Enalapril maleate is an orally active angiotensin-converting enzyme inhibitor. Enalapril maleate blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril maleate inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril maleate attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril maleate reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril maleate is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .
Cat. No.: HY-75992
CAS No.: 74007-20-8
Target:
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology Endocrinology
trans-Doxercalciferol is an isomer of Doxercalciferol (HY-32348). Doxercalciferol is a vitamin D receptor agonist. Doxercalciferol reduces proteinuria, podocyte injury, mesangial expansion, extracellular matrix accumulation, macrophage infiltration, oxidative stress, proinflammatory cytokines, profibrotic growth factors, renal neutral lipid accumulation, albuminuria and glomerulosclerosis. Doxercalciferol alleviates high-salt diet-induced myocardial hypertrophy. trans-Doxercalciferol is used for the research of diet-induced obesity-related nephropathy, diabetic nephropathy, myocardial hypertrophy, cardiac dysfunction and secondary hyperparathyroidism .
Cat. No.: HY-179041
CAS No.: 924851-91-2
Target:
PGE synthase Prostaglandin Receptor MDM-2/p53 Amino acid Transporter Glutathione Peroxidase Ferroptosis
Research Areas:
SZ0232 is a selective mPGES-2 inhibitor. SZ0232 binds to the active site of mPGES-2 via hydrogen bonds and π-π stacking, reduces the production of prostaglandin E2 (PGE2) and blocks the PGE2-EP3 pathway. SZ0232 regulates Ferroptosis by activating the heme-dependent p53/SLC7A11/GPX4 axis, inhibits lipid peroxidation, and protects renal tubules. SZ0232 enhances glucose-stimulated insulin secretion, inhibits β-cell senescence, and improves glucose homeostasis. SZ0232 reduces renal lipid accumulation, alleviates fibrosis, and ameliorates renal dysfunction in diabetic mice. SZ0232 inhibits renal cyst growth in polycystic kidney disease models. SZ0232 exhibits an insulinotropic effect that strengthens with the increase of animal age. SZ0232 can be used in studies related to type 2 diabetes, acute kidney injury, diabetic kidney disease, and autosomal dominant polycystic kidney disease .
Cat. No.: HY-B0331B
CAS No.: 149404-21-7
Synonyms: MK-421 sodium
Research Areas:
Cardiovascular Disease Neurological Disease Metabolic Disease
Enalapril sodium (MK-421 sodium) is an orally active angiotensin-converting enzyme inhibitor. Enalapril sodium blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril sodium inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril sodium attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril sodium reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril sodium is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .
Cat. No.: HY-171336
CAS No.: 357625-50-4
Target:
Research Areas:
TRC4186 is a potent advanced glycation end-product (AGE) breaker . TRC4186 breaks advanced glycation end-products, reduces their tissue accumulation, and decreases AGE burden. TRC4186 improves endothelial and myocardial function, preserves cardiac function, retards renal dysfunction, and reduces renal dysfunction severity. TRC4186 downregulates brain natriuretic peptide and IL-6 expression. TRC4186 can be used for the research of diabetic macro- and microvascular complications, diabetic heart failure, diabetic renal failure, hypertension, diabetes, diabetic cardiomyopathy, and diabetic nephropathy .
Cat. No.: HY-106661
CAS No.: 320777-05-7
Target:
Research Areas:
GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction .
Cat. No.: HY-128442R
CAS No.: 937-34-8
Synonyms: Phenyl hydrogen sulfate (Standard)
Cat. No.: HY-B0331S1
CAS No.: 1356847-94-3
Synonyms: MK-421-d3
Cat. No.: HY-153149
CAS No.: 945457-84-1
Synonyms: FM101
Research Areas:
LJ-2698 (FM101) is an orally active adenosine A3 receptor (Adenosine A3 Receptor) antagonist . LJ-2698 blocks adenosine A3 receptor-dependent pro-inflammatory JNK, ERK, and NF-κB signaling pathways. LJ-2698 prevents alveolar cavity enlargement, restores pulmonary function, and inhibits matrix metalloproteinase activity and pulmonary cell apoptosis (apoptosis) in mice . LJ-2698 induces mitochondrial dysfunction, necroptosis, and intrinsic apoptosis. LJ-2698 ameliorates renal injury in mice with diabetic nephropathy, and alleviates diet-induced hepatic inflammation and fibrosis. LJ-2698 can be used in the research of emphysema, diabetic nephropathy, and metabolic dysfunction-associated steatotic liver disease .
Cat. No.: HY-N18656
CAS No.: 90131-48-9
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
